2-year YOSEMITE and RHINE results show faricimab reduces treatment burden in patients with DMO

May 5, 2022

Video

Dr Jennifer I. Lim reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular oedema.

Emily Kaiser, editor of Modern Retina™, sits down with Dr Jennifer I. Lim to discuss her ARVO 2022 presentation, “Efficacy, durability, and safety of faricimab in diabetic macular oedema: 2-year results from the phase 3 YOSEMITE and RHINE trials.” YOSEMITE and RHINE trials had previously shown noninferiority between faricimab and aflibercept for the treatment of diabetic macular oedema (DMO), and the 2-year results showed that up to 60% of patients could be dosed with faricimab every 16 weeks and 70% of patients could be dosed every 12 weeks following 4 loading doses.

Industry-sponsored satellite symposia at the 23rd EURETINA Congress

September 27th 2023

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

September 8th 2023

Impact of personalised faricimab dosing in neovascular AMD

September 7th 2023

Industry-sponsored satellite symposia at the 23rd EURETINA Congress

September 27th 2023

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

September 8th 2023

Impact of personalised faricimab dosing in neovascular AMD

September 7th 2023

Related Content

A bridge and bicycles in Amsterdam. Image credit: ©andreykr – stock.adobe.com

Industry-sponsored satellite symposia at the 23rd EURETINA Congress

September 27th 2023

Article

Attendees can take advantage of many satellite symposia, sponsored by industry and feauring experts from around the world

A row of houses in historic Amsterdam. Image Credit: ©Yasonya – stock.adobe.com

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Article

Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops

A digital illustration of an eye with charts and numbers imposed atop it. Image credit: ©ArticMinimal – stock.adobe.com

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Article

The AI retinal scanning model will be free to use for all institutions

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Article

The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.